Next Phase Newsletter

A micro VC fund focuses on Angel to Series A stage companies across various sectors, including pharmaceutical, medical device and healthcare IT. The typical investment size is no more than $500,000, but the group will syndicate with other investors for larger investments. The firm looks to make investments in US companies with markets in US and/or China.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed round and series A rounds. Historically, the fund has been active in life science companies developing synthetic organelles-based research tools, nanoparticle research reagents and devices, web-based EMR system, proprietary screening and diagnostic tests for cancer, drug authentication platform and patient recovery technologies.

The firm focuses on investments in private companies and typically invests in pre-revenue companies with strong and experienced management team. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor group focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Korea-based biopharmaceutical company that delivers life-saving and life-sustaining protein therapies and vaccines, has been dedicated to quality healthcare solutions more than half a century. The firm is open to global investment and licensing opportunities.

The firm’s R&D portfolio utilizes its expertise in plasma protein fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative therapeutics that address unmet medical needs and enhance current treatments in areas including Immunology, Hematology, rare disease, plasma protein therapies and vaccines. The firm is committed to broadening medical and scientific knowledge pertaining to its products, disease states of interest. The firm is actively looking for partners to help the firm grow the company’s businesses.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Russian venture capital firm manages a newly raised fund co-invested by the Russian Government. The firm focused mainly on Series A and B investments and a typical allocation is around $2 million. The firm is looking for investment opportunities and partnerships that would include a “Russian angle”, i.e. a certain part of development is to be carried out in Russia. The firm is looking to make 5 investments over the next year. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The firm focused mainly on breakthrough technologies in therapeutics, diagnostics, medical devices and digital health sectors, addressing unmet medical needs in Russia and globally. Therapeutic indications of primary interest include oncology, inflammation, orphan, metabolic, cardiovascular, infectious diseases and pain management. The firm focuses on companies that already entered clinical stage. The firm prefers to work with therapeutics companies that are phase I and phase II of clinical trials but will consider pre-clinical stage companies as long as they have proof-of-concept and are ready to go to clinical stage. For medical devices, diagnostics, and medical IT, the firm prefers to work companies that are in clinical phase or on the market.

The firm is flexible regarding the management team experience, but the firm will only consider Russian-based companies or foreign companies that have (or are ready to have) Russia angles – companies that seek to conduct R&D in Russia, contract manufacturing, etc. When investing in Russia-based companies, the firm can lead the rounds and act as a value-added investor by providing their local resources, and the firm will seek to take a board seat on the company’s board on a case by case basis. The firm is open to syndication as well, especially when dealing with companies that are based outside of Russia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.